Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization

Archives of Internal Medicine

Volumn 165, Issue 1, 2005, Pages 49-54

  Olson, Kari L ^a,b,c   Rasmussen, Jon ^a,b   Sandhoff, Brian G ^a,b   Merenich, John A ^a,b  

^a Clinical Pharmacy Cardiac Risk Service   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATIN;

AGED; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEALTH MAINTENANCE ORGANIZATION; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; MOLECULAR WEIGHT; OUTCOMES RESEARCH; PRIORITY JOURNAL; RECIDIVISM; RECURRENCE RISK; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; COHORT STUDIES; COLORADO; CORONARY ARTERIOSCLEROSIS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; MALE; MIDDLE AGED; PHARMACY SERVICE, HOSPITAL; PREVENTIVE HEALTH SERVICES; PROGRAM EVALUATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 11844305879     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.165.1.49     Document Type: Article

References (24)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383-1389.
2. Sacks FM, Pfeffer MA, Moye LA, et al; Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
3. The Long Term Intervention with Pravastatin in lschaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
4. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with Simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
5. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP). Arch Intern Med. 2000;160:459-467.
6. Olson KL, Tsuyuki RT. Patients' achievement of cholesterol targets: a cross-sectional evaluation. Am J Prev Med. 2003;25:339-342.
7. Olson KL, Bungard TJ, Tsuyuki RT. Cholesterol risk management: a systematic examination of the gap from evidence to practice. Pharmacotherapy. 2001;21:807-817.
8. Fonarow GC, French WJ, Parsons LS, et al. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation. 2001;103:38-44.
9. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust. 1996;164:208-211.
10. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of stain therapy in elderly patients. JAMA. 2002;288:455-461.
11. Expert Panel on Detection. Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-2497.
12. Labresh KA, Gliklich R, Liljestrand J, et al. Using "get with the guidelines" to improve cardiovascular secondary prevention. Jt Comm J Qual Saf. 2003;29:539-550.
13. Merenich JA, Lousberg GT, Brennan SH, et al. Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed-care environment (the Rocky Mountain Kaiser Permanente experience). Am J Cardiol. 2000;85:36A-42A.
14. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1999;83:1303-1307.
15. Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, LaRosa J. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol. 1998;82:61-65.
16. Madlon-Kay DJ. Family physician recognition and treatment of severe hypercholesterolemia. J Fam Pract. 1987;24:54-56.
17. The Clinical Quality Improvement Network (CQIN) Investigators. Low incidence of assessment and modification of risk factors in acute care patients at high-risk for cardiovascular events, particularly among females and the elderly. Am J Cardiol. 1995;76:570-573.
18. Brown AS, Cofer LA. Lipid management in a private cardiology practice (the Midwest Heart Experience). Am J Cardiol. 2000;85:18A-22A.
19. Robinson JG, Conroy C, Wickemeyer WJ. A novel telephone-based system for management of secondary prevention to a low-density lipoprotein cholesterol ≤100 mg/dL. Am J Cardiol. 2000;85:305-308.
20. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the study of cardiovascular risk intervention by pharmacists (SCRIP). Arch Intern Med. 2002;162:1149-1155.
21. Tsuyuki RT, Olson KL, Dubyk AM, Schindel T, Johnson JA, Ogle B. Effect of community pharmacy intervention on cholesterol levels in patients at high risk of cardiovascular events: the second study of cardiovascular risk intervention by pharmacists (SCRIP-plus). Am J Med. 2004;116:130-133.
22. Ockene IS, Heber JR, Ockene JK, et al. Effect of physician-delivered nutrition counseling training and an office-support program on saturated fat intake, weight, and serum lipid measurements in a hyperlipidemic population: Worcester Area Trial for Counseling in Hyperlipidemia (WATCH). Arch Intern Med. 1999;159:725-731.
23. Shaffer J, Wexler LF. Reducing low-density lipoprotein cholesterol levels in an ambulatory care system: results of a multidisciplinary collaborative practice lipid clinic compared with traditional physician-based care. Arch Intern Med. 1995;155:2330-2335.
24. Harris DE, Burgess N, Gipson GW, Pearson TA. Lipid lowering in a multidisciplinary clinic compared with primary physician management. Am J Cardiol. 1998;81:929-933.